Early detection of Alzheimer's disease with a new imaging approach
Official title: Early Detection of Alzheimer’s Disease Using a Novel ImmunoPET Conjugate
Funded at Aivocode, LLP · NIH-11403170 · Data updated 2026-11-12
A new imaging agent targeting CTGF could help detect Alzheimer's disease early, potentially before deep brain damage and symptoms appear.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aivocode, LLP NIH-funded |
| Lab location | 1 site (Encinitas, UNITED STATES) |
| Project start | September 16, 2026 |
| Project end | September 15, 2027 |
| Funding year | 2026 |
| Award (this year) | $499,880 |
| NIH project number | 1R43AG099485-01A1 |
| Project ID | NIH-11403170 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults at risk for or suspected of having Alzheimer’s disease who could benefit from early diagnostic imaging.
✕Less likely to help
Individuals without risk factors or those with advanced disease where early imaging would not change management.
What this research studies
This project aims to develop an imaging tool that identifies a protein called CTGF in the brains of people at risk for Alzheimer’s disease. By using novel single-domain antibodies, the team hopes to visualize CTGF with PET scans to flag early disease changes. The work focuses on translating basic discovery into a diagnostic probe that could be used in people who might benefit from early intervention. If successful, this could lead to earlier diagnosis and better chances to slow or manage the disease.
Why it matters
Potential benefit: If successful, patients could get an earlier and more accurate diagnosis of Alzheimer's disease, allowing for timely care and planning.
How similar studies have gone: Earlier imaging approaches have shown promise, but this project focuses on a CTGF-targeted imaging agent for earlier detection.
Where this research is happening
-
Aivocode, LLP
Encinitas, United States Active
Researchers
- Principal investigator: Hussain, Sazid — Aivocode, LLP
- Study coordinator: Hussain, Sazid
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.